Secretive biotech unicorn Moderna unveils research pipeline, financials
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
San Francisco
MODERNA Therapeutics Inc, one of the best-funded private biotechnology companies in the US, unveiled its long-secret research and development pipeline on Monday, including experimental vaccines, cancer treatments and a cardiovascular therapy.
The Cambridge, Massachusetts-based startup has about US$1.3 billion in cash on hand from investors, pharmaceutical partners and government grants, according to a presentation on Monday at the JPMorgan Chase & Co Healthcare Conference in San Francisco. It's privately valued at about US$5 billion, according to a person familiar with the matter who asked not to be identified because the matter wasn't public.
Share with us your feedback on BT's products and services
